Online citations, reference lists, and bibliographies.

A Review Of The Novel Application And Potential Adverse Effects Of Proton Pump Inhibitors

Li-Yuan Yu, Lu-ning Sun, Xue-hui Zhang, Yue-qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hongwen Zhang, Yong-Qing Wang
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Proton pump inhibitors (PPIs) are known as a class of pharmaceutical agents that target H+/K+-ATPase, which is located in gastric parietal cells. PPIs are widely used in the treatment of gastric acid-related diseases including peptic ulcer disease, erosive esophagitis and gastroesophageal reflux disease, and so on. These drugs present an excellent safety profile and have become one of the most commonly prescribed drugs in primary and specialty care. Except for gastric acid-related diseases, PPIs can also be used in the treatment of Helicobacter pylori infection, viral infections, respiratory system diseases, cancer and so on. Although PPIs are mainly used short term in patients with peptic ulcer disease, nowadays these drugs are increasingly used long term, and frequently for a lifetime, for instance in patients with typical or atypical symptoms of gastroesophageal reflux disease and in NSAID or aspirin users at risk of gastrotoxicity and related complications including hemorrhage, perforation and gastric outlet obstruction. Long-term use of PPIs may lead to potential adverse effects, such as osteoporotic fracture, renal damage, infection (pneumonia and clostridium difficile infection), rhabdomyolysis, nutritional deficiencies (vitamin B12, magnesium and iron), anemia and thrombocytopenia. In this article, we will review some novel uses of PPIs in other fields and summarize the underlying adverse reactions.
This paper references
10.1016/S0140-6736(12)61579-7
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou (2013)
Effects of different proton pump inhibitors on cardiac contractility in isolated human failing myocardium.
Samuel Sossalla (2011)
selective activity against Helicobacter pylori
(1991)
10.1111/J.1349-7006.2007.00642.X
Retraction: Blockage of intracellular proton extrusion with proton pump inhibitor induces apoptosis in gastric cancer.
M. Yeo (2008)
10.1371/journal.pone.0112558
The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis
C. Park (2014)
10.1186/1471-2466-14-21
Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
Emily A Dimango (2014)
10.1371/journal.pone.0124653
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population
Nigam Haresh Shah (2015)
10.1111/jgh.13418
Treatment of Helicobacter pylori infection: Where are we now?
Jyh-Ming Liou (2016)
10.1016/j.jacc.2011.12.024
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andrew L Frelinger (2012)
10.1001/jama.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1053/j.gastro.2012.06.044
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
Gary W. Falk (2012)
10.1021/mp300323q
Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium.
J. Bai (2012)
10.1111/dote.12237
Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required.
Seth Lipka (2016)
10.18632/oncotarget.5319
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma
Yoo-Young Lee (2015)
10.1016/j.taap.2007.03.029
Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid.
Xinming Qi (2007)
10.1016/j.amjmed.2005.02.007
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
10.1038/sj.onc.1206053
Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis
L. A. Shchepina (2002)
Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases.
Michael R. Boyd (2001)
10.1038/nm0609-610
Stomaching calcium for bone health
Brendan F Boyce (2009)
10.1016/j.ijid.2015.06.007
Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature.
M. Ogielska (2015)
10.1016/S0140-6736(08)61159-9
Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial
K. Fukase (2008)
10.1111/j.1532-5415.2009.02349.x
A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients.
T. Sasaki (2009)
Manipulating tumor acidification as a cancer treatment strategy.
Mark F. Mccarty (2010)
10.1370/afm.1243
Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies
Chun-Sick Eom (2011)
10.5217/ir.2015.13.3.227
'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?
Nathan S. S. Atkinson (2015)
10.1371/journal.pone.0126432
Proton Pump Inhibitors Inhibit Pancreatic Secretion: Role of Gastric and Non-Gastric H+/K+-ATPases
Jing Wang (2015)
10.1111/j.1365-2036.2011.04770.x
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
Javier P. Gisbert (2011)
10.1007/s11938-014-0041-8
Translating New Developments in Eosinophilic Esophagitis Pathogenesis into Clinical Practice
Edaire Cheng (2015)
10.1177/1753465810392264
A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD
T. Sasaki (2011)
10.1517/13543776.2013.741121
H+/K+-ATPase inhibitors: a patent review
Hao Li (2013)
10.1016/S2213-2600(16)00097-7
Management of chronic obstructive pulmonary disease beyond the lungs.
Lowie Vanfleteren (2016)
10.3748/WJG.V16.I10.1279
Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori.
Zhan Zhang (2010)
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
10.3748/wjg.v21.i45.12954
Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.
Ping-I Hsu (2015)
10.1016/j.bbrc.2006.04.170
Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells.
Jan Carl Becker (2006)
10.1097/MD.0000000000002104
A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection
Ping-I Hsu (2015)
10.1161/CIRCULATIONAHA.106.666008
Negative Inotropy of the Gastric Proton Pump Inhibitor Pantoprazole in Myocardium From Humans and Rabbits: Evaluation of Mechanisms
W. Schillinger (2007)
10.1007/s00228-010-0821-6
Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers
Yongqing Wang (2010)
10.1046/j.1523-5378.1998.08024.x
Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
Masafumi Nakao (1998)
10.1186/s12967-014-0225-y
High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors
Enrico Pierluigi Spugnini (2014)
10.1080/07315724.1995.10718522
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C. Serfaty-Lacrosniere (1995)
10.1093/jac/dkg085
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori.
L Gatta (2003)
10.1186/s13046-015-0194-x
Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer
Bi-yun Wang (2015)
10.2165/11531320-000000000-00000
Drug-Drug Interaction Profiles of Proton Pump Inhibitors
Ryuichi Ogawa (2010)
10.1111/j.1365-2036.2005.02611.x
Review article: the long-term use of proton-pump inhibitors.
A. Raghunath (2005)
10.1016/j.canlet.2016.04.015
Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma.
Andrea Canitano (2016)
10.3748/wjg.v21.i48.13548
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Yoshimasa Saito (2015)
10.1503/cmaj.092129
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis
Chun-Sick Eom (2011)
10.1097/MOG.0b013e328358d5b9
Proton pump inhibitors: potential adverse effects
Neena S Abraham (2012)
10.1007/s00228-015-1834-y
Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway
S. Feng (2015)
10.1158/0008-5472.CAN-11-3851
Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
D. Kim (2012)
10.1586/17512433.2013.811206
Perils and pitfalls of long-term effects of proton pump inhibitors
Sheila M. Wilhelm (2013)
10.9778/cmajo.20140074
Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study.
T. Antoniou (2015)
10.1038/sj.bjc.6605452
Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
I. Zlobec (2010)
10.18176/JIACI.0002
Eosinophilic Esophagitis: An Evidence-Based Approach to Therapy.
Jesús González-Cervera (2016)
10.1503/cmaj.120954
Pantoprazole-induced acute interstitial nephritis
Sheila Klassen (2013)
10.1007/s00228-010-0949-4
Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers
Yongqing Wang (2010)
10.1111/febs.12478
Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.
João Costa-Rodrigues (2013)
10.1111/apt.13537
Systematic review with network meta-analysis: comparative effectiveness of topical steroids vs. PPIs for the treatment of the spectrum of eosinophilic oesophagitis.
S. Lipka (2016)
10.1128/AAC.35.3.490
Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
T. Iwahi (1991)
10.1016/j.gtc.2010.08.009
The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.
Neehar D. Parikh (2010)
10.3748/wjg.v17.i35.3971
A new look at anti-Helicobacter pylori therapy.
Seng-Kee Chuah (2011)
10.1016/S1476-5586(03)80037-4
Extracellular acidification alters lysosomal trafficking in human breast cancer cells.
K. Glunde (2003)
Comparative risk of ischemic
CE Leonard
10.1136/gut.2007.125658
The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis
Angelo Zullo (2007)
10.1158/0008-5472.CAN-06-4095
Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
A. de Milito (2007)
10.1136/gutjnl-2013-304738
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
K. Filion (2013)
10.1021/tx5005198
Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway.
Un-Ho Jin (2015)
10.1681/ASN.2015121377
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Yan Xie (2016)
10.1126/scitranslmed.3010277
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis
Yo Matsuo (2014)
10.1038/nrgastro.2010.210
Optimal therapy for Helicobacter pylori infections
Emiko Rimbara (2011)
pylori
S Zhao (1998)
10.1001/archinternmed.2011.199
Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg.
Tania W Furlanetto (2011)
10.3892/OL.2015.3912
Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2.
Yonghua Shen (2016)
Inventor method of using (H/K)ATPase inhibitors as antiviral agents
AEBDP Moormann (2005)
10.1007/s12328-017-0725-4
Diagnosis and treatment of eosinophilic esophagitis in clinical practice
Yasuhiko Abe (2017)
10.5009/gnl14135
A Proton Pump Inhibitor’s Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study
Yunju Jo (2015)
10.1093/qjmed/hcq021
Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series.
John Duncan Mackay (2010)
10.4239/wjd.v6.i10.1122
Effect of proton pump inhibitors on glycemic control in patients with diabetes.
Kohzo Takebayashi (2015)
10.1038/ki.2014.74
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use
Mei-Ling Blank (2014)
10.1038/cddis.2010.67
Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells
M. Marino (2010)
10.1158/1535-7163.MCT-13-0484
V-ATPase Inhibition Regulates Anoikis Resistance and Metastasis of Cancer Cells
Christina Maria Schempp (2014)
10.1111/j.1365-2036.2010.04284.x
Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia.
Jennie Johnstone (2010)
10.1001/jamainternmed.2015.7927
Adverse Effects Associated With Proton Pump Inhibitors.
Adam J Schoenfeld (2016)
10.12688/f1000research.6085.2
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry
Jason S Long (2015)
10.12688/f1000research.6085.1
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.
Jason S Long (2015)
10.1371/journal.pone.0020143
Omeprazole Inhibits Proliferation and Modulates Autophagy in Pancreatic Cancer Cells
Andrej Udelnow (2011)
10.1161/STROKEAHA.114.006866
Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors
C. Leonard (2015)
10.1007/s40256-014-0073-4
Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers
Tommy B. Andersson (2014)
10.1186/1471-2466-14-1
Determinants of arterial stiffness in COPD
Surya P Bhatt (2014)
Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis
JP Bai (2012)
10.1136/gut.34.11.1559
Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats.
Ian D Penman (1993)
10.1002/1097-4652(200101)186:1<65::AID-JCP1000>3.0.CO;2-X
Intracellular apoptosis-inducing factor is induced by a vacuolar type H+-ATPase inhibitor in B lineage cells.
Shusuke Hashimoto (2001)
10.1128/AAC.02922-14
Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection
P. Hsu (2014)
10.1126/science.1160809
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
M. V. Vander Heiden (2009)
10.1016/j.ejphar.2004.12.042
The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells.
T. Sasaki (2005)
10.1634/theoncologist.2011-0431
Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.
Shewit Bezabeh (2012)
10.1016/j.cca.2008.02.003
Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.
Yalin Li (2008)
10.1136/bcr-2014-205165
From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor
Allon Eyal (2014)
10.3748/wjg.v20.i28.9321
Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.
Shan Zhao (2014)
10.1093/ndt/gfu326
Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury.
Manuel Praga (2015)
Eosinophilic esophagitis that develops during therapy with proton pump inhibitors : case series and possible mechanisms.
Rok Orel (2016)
10.1128/AAC.44.2.458-461.2000
In Vitro Activities of Rabeprazole, a Novel Proton Pump Inhibitor, and Its Thioether Derivative Alone and in Combination with Other Antimicrobials against Recent Clinical Isolates ofHelicobacter pylori
Y. Kawakami (2000)
Blockage of intracellular proton extrusion with proton extrusions with proton pump inhibitor induces apoptosis in gastric cancer.
M. Yeo (2008)
10.1158/1940-6207.CAPR-10-0033
Novel Application of Proton Pump Inhibitor for the Prevention of Colitis-Induced Colorectal Carcinogenesis beyond Acid Suppression
Y. Kim (2010)
10.1007/BF03264647
Acute interstitial nephritis
D. Kleinknecht (1980)



This paper is referenced by
10.2147/DDDT.S260565
Effects of Calcium and Annatto Tocotrienol Supplementation on Bone Loss Induced by Pantoprazole in Male Rats
K. Chin (2020)
10.3748/wjg.v24.i38.4369
Sex-specific effects of Eugenia punicifolia extract on gastric ulcer healing in rats
Larissa Lucena Périco (2018)
10.1016/J.RGMXEN.2018.05.011
Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico.
Max Schmulson (2019)
10.1016/j.cbi.2019.05.011
Hesperidin, a citrus flavanone glycoside, accelerates the gastric healing process of acetic acid-induced ulcer in rats.
Luísa Mota da Silva (2019)
10.1097/MOG.0000000000000392
Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion
Mitchell L. Schubert (2017)
10.5125/jkaoms.2019.45.3.135
Proton pump inhibitor intake negatively affects the osseointegration of dental implants: a retrospective study
Mehmet Ali Altay (2019)
10.2147/CIA.S146009
Potentially inappropriate medications in hospitalized older patients: a cross-sectional study using the Beers 2015 criteria versus the 2012 criteria
Xiaolin Zhang (2017)
10.1155/2018/5257285
Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences
Gloria Ortiz-Guerrero (2018)
10.1111/tbj.13519
Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: A population-based cohort study.
Dah-Ching Ding (2019)
10.1080/17425255.2018.1461835
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
Nihal M. El Rouby (2018)
10.1177/2050640618795928
Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)
Lukas Sturm (2018)
10.1016/j.phrs.2019.104606
Effects of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors.
He-Jian Zhang (2019)
10.1016/J.RGMX.2018.02.008
Síntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multicéntrica en México
Max Schmulson (2019)
10.1155/2017/7089697
Gastroprotective Value of Berries: Evidences from Methanolic Extracts of Morus nigra and Rubus niveus Fruits
Luciane Angela Nottar Nesello (2017)
10.1016/j.rgmx.2018.02.008
Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico.
Max Schmulson (2019)
L’optimisation thérapeutique chez le sujet âgé en SSR : mise en œuvre et suivi en ville
Alicia Pic (2017)
10.1002/jcph.1329
Negative Association of Proton Pump Inhibitors With Subsequent Development of Breast Cancer: A Nationwide Population‐Based Study
Chao-hung Chen (2019)
10.4172/2155-6148.1000819
The Effectiveness of Standard Single Dose Omeprazole vs. High Dose Continuous Infusion in High-risk Critically Ill Patients
Ezzeldin Ibrahim (2018)
10.18314/igh.v1i1.1185
Long Term Use of Proton Pump Inhibitors: Where to Draw the Line
Munirul M. Haque (2018)
10.1002/adtp.202000034
Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention
Aynur Abdulla (2020)
10.1002/14651858.CD013113
Proton pump inhibitors for chronic obstructive pulmonary disease
Shino Kikuchi (2018)
10.23876/j.krcp.2018.37.1.59
Association of proton pump inhibitor use with renal outcomes in patients with coronary artery disease
Nam-jun Cho (2018)
10.1016/j.ejphar.2017.12.042
The natural flavonoid myricetin inhibits gastric H+, K+‐ATPase
Yuu Miyazaki (2018)
10.1016/j.biopha.2017.12.020
Essential oil of Cymbopogon citratus (lemongrass) and geraniol, but not citral, promote gastric healing activity in mice.
Larissa Venzon (2018)
Anti-Gastric Ulcer Activity of Aqueous Extract of Terminalia Arjuna Against Helicobacter Pylori Lipopolysaccharide
Devi (2018)
10.1016/j.bpg.2017.10.006
The interaction between smoking, alcohol and the gut microbiome.
Gabriele Capurso (2017)
10.1002/ddr.21535
Pharmacodynamic interaction of 3α-hydroxymasticadienonic acid and diligustilide against indomethacin-induced gastric damage in rats.
Elizabeth Arlen Pineda-Peña (2019)
10.1097/MD.0000000000013700
Increased risk of appendectomy in patients with gastroesophageal reflux disease
So Young Kim (2018)
10.1155/2019/3546258
Gastroprotective Effects of Paeonia Extract Mixture HT074 against Experimental Gastric Ulcers in Rats
Young-Sik Kim (2019)
10.3390/ijms21010323
The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses
Paulien Vinke (2020)
10.1016/j.bcp.2019.113673
Schisantherin A induces cell apoptosis through ROS/JNK signaling pathway in human gastric cancer cells.
Zishu Wang (2019)
10.1007/s00228-017-2372-6
Safety, pharmacokinetics, and pharmacodynamics of S-(−)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects
Hui-Wen Jiao (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar